Lapatinib or Trastuzumab? Which Anti-Her2 Treatment is More Effective in the Treatment of Patients with Her2-Positive Breast Cancer with Brain Metastases? An Anatolian Society of Medical Oncology Study

Kaplan, Muhammet AliIşıkdoğan, AbdurrahmanKoca, DoğanKüçüköner, MehmetGümüşay, ÖzgeYıldız, RamazanÖztop, İlhan2020-03-262020-03-262012Kaplan, M. A., Işıkdoğan, A., Koca, D., Küçüköner, M., Gümüşay, Ö., Yıldız, R., Öztop, İ., (2012). Lapatinib or Trastuzumab? Which Anti-Her2 Treatment is More Effective in the Treatment of Patients with Her2-Positive Breast Cancer with Brain Metastases? An Anatolian Society of Medical Oncology Study. Journal of Clinical Oncology, 30(15).0732-183X1527-7755https://hdl.handle.net/20.500.12395/2818948th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 01-06, 2012 -- Chicago, IL[Abstract not Available]eninfo:eu-repo/semantics/closedAccessLapatinib or Trastuzumab? Which Anti-Her2 Treatment is More Effective in the Treatment of Patients with Her2-Positive Breast Cancer with Brain Metastases? An Anatolian Society of Medical Oncology StudyConference Object3015WOS:000318009800398Q1